Drug intelligence / Profile preview

TPX-112 + TPX-113

Development stage: Preclinical
Lead developer: Tego Science
Modality: Cell Therapies
Administration: Topical

Overview

TPX-112 + TPX-113 is a preclinical-stage cell therapy combination being developed by Tego Science (Tego Global) for the repair of oral mucosal defects. The therapy consists of a combination of autologous cultured mucosal cells (TPX-112) and allogeneic cultured mucosal cells (TPX-113). This dual approach aims to restore damaged oral mucosal tissue by leveraging the regenerative properties of both patient-derived and donor-derived mucosal cells. As of 2024, the program remains in the preclinical development phase and is part of Tego Science's regenerative medicine pipeline.

Other names: autologous/allogeneic cultured mucosal cells

Beyond the preview

Go deeper on TPX-112 + TPX-113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPX-112 + TPX-113.

Explore the full profile